Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes

Science. 2016 Apr 15;352(6283):349-53. doi: 10.1126/science.aad9279.

Abstract

Drug resistance compromises control of malaria. Here, we show that resistance to a commonly used antimalarial medication, atovaquone, is apparently unable to spread. Atovaquone pressure selects parasites with mutations in cytochrome b, a respiratory protein with low but essential activity in the mammalian blood phase of the parasite life cycle. Resistance mutations rescue parasites from the drug but later prove lethal in the mosquito phase, where parasites require full respiration. Unable to respire efficiently, resistant parasites fail to complete mosquito development, arresting their life cycle. Because cytochrome b is encoded by the maternally inherited parasite mitochondrion, even outcrossing with wild-type strains cannot facilitate spread of resistance. Lack of transmission suggests that resistance will be unable to spread in the field, greatly enhancing the utility of atovaquone in malaria control.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anopheles / parasitology*
  • Antimalarials / pharmacology*
  • Antimalarials / therapeutic use
  • Atovaquone / pharmacology*
  • Atovaquone / therapeutic use
  • Cell Line
  • Cytochromes b / genetics*
  • Drug Resistance / genetics*
  • Genes, Mitochondrial / genetics
  • Humans
  • Life Cycle Stages / drug effects
  • Life Cycle Stages / genetics
  • Malaria / drug therapy
  • Malaria / parasitology*
  • Malaria / transmission
  • Male
  • Mice
  • Mitochondria / genetics*
  • Mutation
  • Plasmodium berghei / drug effects*
  • Plasmodium berghei / genetics
  • Plasmodium berghei / growth & development
  • Selection, Genetic

Substances

  • Antimalarials
  • Cytochromes b
  • Atovaquone